- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04913597
A Study of Switching Avatrombopag and Rh-TPO in ITP
May 29, 2021 updated by: Fuhaixia, Peking University People's Hospital
A Prospective Observational Study of Switching Avatrombopag and Rh-TPO in Chinese Adult Patients With Primary Immune Thrombocytopenia
Thrombopoietin receptor agonists (TPO-RAs) represent a highly effective and well-tolerated second-line ITP treatment that provides excellent responses.If there is cross-resistance between 2 drugs for the treatment of adult ITP is still unkonwn.The purpose of this study is to investigate the efficacy and safety of switching avatrombopag and rh-TPO in adults with ITP.
Study Overview
Status
Not yet recruiting
Conditions
Detailed Description
Thrombopoietin Receptor Agonists (TPO-RAs) are novel treatments for patients with chronic Primary Immune Thrombocytopenia (ITP).
According to the findings of mechanism-based studies, rhTPO competes with endogenous TPO for binding to TPO-R while avatrombopag has an additive effect with endogenous TPO, indicating that the treatment mechanism and side-effect profiles could be somewhat different between these drugs.
If there is cross-resistance between 2 drugs for the treatment of adult ITP is still no answer.
The purpose of this study is to investigate the efficacy and safety of switching avatrombopag and rh-TPO in adults with ITP.This is a non-interventional study.
Patients who fail previous steroids and receive rh-TPO and then switch to avatrombopag or vice versa will be enrolled.
The reason for switch will be recorded.
The efficacy, safety, and patient/physician preference will be assessed and compared between the two agents.
Study Type
Observational
Enrollment (Anticipated)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Haixia Fu, MD
- Phone Number: 8610-88324577
- Email: fuhaixia_210@163.com
Study Contact Backup
- Name: Yun He, MD
- Phone Number: 18910504949
- Email: heyun04@126.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
adult ITP patients
Description
Inclusion Criteria:
1.18 years or older 2.Primary ITP 3.Failed initial glucocorticosteroid treatment, 4.Applying rhTPO or Eltrombopag as subsequent treatment 5.Switch from rh-TPO to eltrombopag or vice versa 6.Normal neutrophils 7.Available follow-up at least 6 weeks after switching
Exclusion Criteria:
- HIV positive status, or active infection of HBV or HCV
- Suffering from a serious or progressive disease, which, in the investigator's judgment, put the subject at undue risk for participation in this study (i.e. cancer or pre-cancer, immunocompromised, uncontrolled diabetes, epilepsy, severe cardio-cerebrovascular disease(s) (i.e. stroke, idiopathic aortic stenosis, aneurysm, hypertrophic obstructive cardiomyopathy, ischaemic heart disease, tachyarrhythmias, severe heart failure [classified as NYHA III-IV], severe lung dysfunctions, etc))
- History of thrombosis plus two or more risk factors as defined in Caprini thrombosis risk assessment model
- Lactating or pregnant women, or WOCBP who are unwilling to use highly effective contraceptive measures during the study period
- Abnormal liver and renal functions: AST or ALT or total bilirubin ≥1.5 × ULN, and/or creatinine ≥176.8 μmol/L
- Women of childbearing potential (WOCBP) that are pregnant or wish to become pregnant during the prospective phase of the study.
- Other conditions which the investigator considers inappropriate for enrollment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Recombinant human thrombopoietin (rh-TPO) group
Patients who fail previous steroids and avatrombopag and then switch to Rh-TPO will be enrolled.
The reason for switch will be recorded.
Patients will be given rh-TPO 300 U/kg once daily for 14 days as initial treatment.
After initial treatment, maintenance therapy were performance.
At initial therapy, rhTPO will be suspended when platelet counts ≥100×10^9 / L. During maintenance therapy, patients with platelet counts >150×10^9 / L will suspend treatment until platelet counts drop to ≤150×10^9 / L. Dosing interval will be prolonged when platelet count is ≥100×10^9 / L to ≤150×10^9 / L. Dose modification is not required when platelet count is ≥30×10^9 / L to <100×10^9 / L. The efficacy, safety, and patient/physician preference will be assessed.
|
Avatrombopag group
Patients who fail previous steroids and rh-TPO and then switch to avatrombopag will be enrolled.
The reason for switch will be recorded.
Patients will be given avatrombopag 20mg once daily as initiate treatment, and adjust the dosage according to the count of platelets.
The maximum dose of avatrombopag is 40mg daily.Avatrombopag will be terminated any time the platelet counts increased above 250×10^9/L.
Dose adjustment of avatrombopag will be allowed to maintain platelet counts between 30×10^9/L and 150×10^9/L.
The efficacy, safety, and patient/physician preference will be assessed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Initial response after switching
Time Frame: 4 weeks
|
Rate of response at 4 weeks after switching from rhTPO to avatrombopag or vise versa
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response rate at 12 weeks after switching
Time Frame: 12 weeks
|
Rate of response at 12 weeks after switching from rhTPO to avatrombopag or vise versa
|
12 weeks
|
Initial response after switching according to the reasons of switching
Time Frame: 4 weeks
|
Rate of response at 1 month after switching according to the reasons of switching,such as lack of efficacy, Platelet count fluctuations, development of adverse events,patient's or doctor's preference
|
4 weeks
|
Rate of response at 12 weeks after switching according to the reasons of switching
Time Frame: 12 weeks
|
Rate of response at 12 weeks after switching according to the reasons of switching,such as lack of efficacy, Platelet count fluctuations, development of adverse events,patient's or doctor's preference
|
12 weeks
|
Time to response
Time Frame: 4 weeks
|
Time to CR or R from switching
|
4 weeks
|
Durable response
Time Frame: 24 weeks
|
The maintenance of platelet count ≥ 30 x 10^9/L, at least 2-fold increase of the baseline count, the absence of bleeding, and no need for rescue medication at the 24 weeks follow-up.
|
24 weeks
|
Incidence of bleeding events
Time Frame: 24 weeks
|
Incidence of clinically significant bleeding as assessed using the world health organization (WHO) bleeding scale
|
24 weeks
|
Immune Thrombocytopenia Patient Assessment Questionnaire (ITP-PAQ)
Time Frame: 24 weeks
|
In all participants ,use ITP-PAQ to assess the Health Related Quality of Life(HRQoL) before and after treatment.
|
24 weeks
|
Functional Assessment of Chronic Illness Therapy fatigue subscale (FACIT-F)
Time Frame: 24 weeks
|
In all participants ,use FACIT-F to assess the Health Related Quality of Life(HRQoL) before and after treatment.
|
24 weeks
|
Safety assessment
Time Frame: 24 weeks
|
Number of Participants with side effects of the drugs
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Haixia Fu, MD, Peking University People's Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013 Jul;98(1):10-23. doi: 10.1007/s12185-013-1382-0. Epub 2013 Jul 3.
- Wormann B. Clinical indications for thrombopoietin and thrombopoietin-receptor agonists. Transfus Med Hemother. 2013 Oct;40(5):319-25. doi: 10.1159/000355006. Epub 2013 Sep 11.
- Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, Cuker A, Despotovic JM, George JN, Grace RF, Kuhne T, Kuter DJ, Lim W, McCrae KR, Pruitt B, Shimanek H, Vesely SK. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019 Dec 10;3(23):3829-3866. doi: 10.1182/bloodadvances.2019000966. Erratum In: Blood Adv. 2020 Jan 28;4(2):252.
- Liu XG, Bai XC, Chen FP, Cheng YF, Dai KS, Fang MY, Feng JM, Gong YP, Guo T, Guo XH, Han Y, Hong LJ, Hu Y, Hua BL, Huang RB, Li Y, Peng J, Shu MM, Sun J, Sun PY, Sun YQ, Wang CS, Wang SJ, Wang XM, Wu CM, Wu WM, Yan ZY, Yang FE, Yang LH, Yang RC, Yang TH, Ye X, Zhang GS, Zhang L, Zheng CC, Zhou H, Zhou M, Zhou RF, Zhou ZP, Zhu HL, Zhu TN, Hou M. Chinese guidelines for treatment of adult primary immune thrombocytopenia. Int J Hematol. 2018 Jun;107(6):615-623. doi: 10.1007/s12185-018-2445-z. Epub 2018 Apr 4.
- Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, Ghanima W, Godeau B, Gonzalez-Lopez TJ, Grainger J, Hou M, Kruse C, McDonald V, Michel M, Newland AC, Pavord S, Rodeghiero F, Scully M, Tomiyama Y, Wong RS, Zaja F, Kuter DJ. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019 Nov 26;3(22):3780-3817. doi: 10.1182/bloodadvances.2019000812.
- Bussel JB. Avatrombopag. Br J Haematol. 2018 Nov;183(3):342-343. doi: 10.1111/bjh.15568. Epub 2018 Oct 23. No abstract available.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
June 20, 2021
Primary Completion (Anticipated)
December 31, 2022
Study Completion (Anticipated)
December 31, 2023
Study Registration Dates
First Submitted
May 29, 2021
First Submitted That Met QC Criteria
May 29, 2021
First Posted (Actual)
June 4, 2021
Study Record Updates
Last Update Posted (Actual)
June 4, 2021
Last Update Submitted That Met QC Criteria
May 29, 2021
Last Verified
May 1, 2021
More Information
Terms related to this study
Other Study ID Numbers
- ITP-SWITCH1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Corticosteroid-resistant or Relapsed ITP
-
Peking University People's HospitalUnknownCorticosteroid-resistant or Relapsed ITPChina
-
Peking University People's HospitalUnknownCorticosteroid-resistant or Relapsed ITPChina
-
National Jewish HealthCompletedCorticosteroid Resistant (CR) AsthmaticsUnited States
-
Assistance Publique - Hôpitaux de ParisUnknownPersistent or Chronic ITPFrance
-
Lin BioScience, IncLin BioScience Pty LtdRecruitingRelapsed or Resistant Acute LeukaemiasTaiwan, Australia
-
OncoMed Pharmaceuticals, Inc.CompletedRelapsed or Refractory Lymphoid MalignanciesUnited States
-
Merck Sharp & Dohme LLCEisai Inc.Active, not recruitingRelapsed or Refractory Solid TumorsUnited States, Argentina, Australia, Belgium, Croatia, Czechia, France, Guatemala, Hungary, Israel, Italy, Korea, Republic of, New Zealand, Peru, Russian Federation, Serbia, South Africa, Spain, Sweden, Turkey
-
OncoMed Pharmaceuticals, Inc.CompletedRelapsed or Refractory Solid TumorsUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisInnovative Therapies For Children with Cancer ConsortiumUnknownRelapsed or Refractory Pediatric TumorFrance, Ireland, Israel, Italy, Spain
-
The University of Texas Health Science Center at...CompletedRefractory or Relapsed Solid TumorsUnited States